Aging is an important risk factor for most common human diseases, including type 2 diabetes, cardiovascular disease, neurodegeneration and Alzheimer?s Disease (AD). However, centenarians and super centenarians have a lower incidence and severity of age-related diseases including AD and related dementias. As part of the NIA-funded U19 entitled ?Genetic Variant-based Drug Discovery Targeting Conserved Pathways of Aging?, we are exploring this genetic differences between successfully aged, healthy centenarians and control individuals with no family history of extreme longevity. Using the centenarian resource at the Albert Einstein College of Medicine, we identified rare genetic variants associated with conserved mechanisms of healthy longevity that are being evaluated functionally in mouse models of aging, including natural aging, for phenotypes relevant for late-life human health, and subsequently will be used as leads for developing and testing small molecules targeting the pathways affected by these rare variants. As part of this effort, we identified rare, longevity associated two amino acid variants in SIRT6 (N308K and A313S) in centenarians. In addition, three longevity- associated non-coding variants (rs350845, rs350843, rs350846) significantly correlated with increased expression of SIRT6 in different human tissues. SIRT6 is a member of the sirtuin family of stress responsive proteins with deacetylase and mono-ADP ribosyltransferase enzymatic activity. SIRT6 regulates multiple pathways involved with aging including DNA repair, telomere maintenance, inflammation and glycolysis. Mice deficient in SIRT6 show multiple signs of premature aging with a lifespan of only a few months and overexpression of SIRT6 extends lifespan in mouse models of accelerated and natural aging. We demonstrated that the SIRT6 centenarian variant improves several SIRT6 activities including deacetylation of H3K56Ac, but not H3K9Ac, DNA repair, lamin A binding and, in particular, ribosylation activity. Importantly, we demonstrated that the natural sulfated polysaccharide fucoidan from brown algae and seaweed stimulates the ribosylation activity of SIRT6, improves DNA repair and reduces markers of senescence. These results demonstrate that either upregulation or increased activity of SIRT6 promote longevity and healthy aging, possibly due to improved genome maintenance and DNA repair, suggesting that SIRT6 can be a clinically-relevant target in humans. Here we propose to examine the effects of over-expression of human SIRT6 on pathology in natural and accelerated aging murine models of AD as well as test the beneficial effects of the SIRT6 ribosylation activator, fucoidan, on AD disease progression. These genetic and pharmacologic approaches will be accomplished in one year through the use of AAV-mediated gene transfer of A and Tau into SIRT6 over-expressing (Sirt6-OE) mice in both WT and mice with accelerated aging (Ercc1-/?). These proposed experiments will document that increasing SIRT6 expression or ribosylation activity is therapeutic for AD and lead to the development of novel approaches to prevent or treat the disease.

Public Health Relevance

Aging is an important risk factor for most common human diseases, including type 2 diabetes, cardiovascular disease, cancer and Alzheimer?s disease (AD). In our U19 grant, we are discovering novel genetic rare variants that may be involved in healthy aging and longevity, including protection from AD that are being validated in mouse models with drugs being develop that target either these rare variants or their pathways. Our U19 team has identified both coding and non-coding rare variants in the gene encoding SIRT6. As part of this Administrative Supplement, the ability of increased SIRT6 expression and/or activity to protect against AD in mouse models will be examined. Similarly, a drug identified that enhances the ribosylation activity of SIRT6 also will be tested for therapeutic activity. These proposed experiments will serve to determine whether SIRT6 is a novel therapeutic target for delaying or reducing the severity of AD.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Program--Cooperative Agreements (U19)
Project #
3U19AG056278-05S2
Application #
10123840
Study Section
Special Emphasis Panel (ZAG1)
Program Officer
Kohanski, Ronald A
Project Start
2017-09-15
Project End
2022-04-30
Budget Start
2020-08-01
Budget End
2021-04-30
Support Year
5
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Albert Einstein College of Medicine
Department
Type
DUNS #
081266487
City
Bronx
State
NY
Country
United States
Zip Code
10461
Lau, Cia-Hin; Suh, Yousin (2018) In vivo epigenome editing and transcriptional modulation using CRISPR technology. Transgenic Res 27:489-509
Xu, Ming; Pirtskhalava, Tamar; Farr, Joshua N et al. (2018) Senolytics improve physical function and increase lifespan in old age. Nat Med 24:1246-1256
Gurkar, Aditi U; Robinson, Andria R; Cui, Yuxiang et al. (2018) Dysregulation of DAF-16/FOXO3A-mediated stress responses accelerates oxidative DNA damage induced aging. Redox Biol 18:191-199
Patil, Prashanti; Niedernhofer, Laura J; Robbins, Paul D et al. (2018) Cellular senescence in intervertebral disc aging and degeneration. Curr Mol Biol Rep 4:180-190
H├ębert, Jean M; Vijg, Jan (2018) Cell Replacement to Reverse Brain Aging: Challenges, Pitfalls, and Opportunities. Trends Neurosci 41:267-279
Lau, Cia-Hin; Suh, Yousin (2017) In vivo genome editing in animals using AAV-CRISPR system: applications to translational research of human disease. F1000Res 6:2153